Bendamustine hydrochloride monohydrate, a type of chemotherapy drug, is an alkylating agent used to treat certain types of cancer, particularly chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL). It works by interfering with the growth of cancer cells, ultimately leading to their destruction. It is grouped under the following drug class(es): Alkylating agents. Its therapeutic use is listed as antineoplastics. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Treakisym (TN), 1H-Benzimidazole-2-butanoic acid, 5-(bis(2-chloroethyl)amino)-1-methyl-, hydrochloride and hydrate. Its PubChem CID is 66600935.
Bendamustine hydrochloride monohydrate
| CAS No | 1374784-02-7 |
|---|---|
| Molecular Formula | C16H24Cl3N3O3 |
| Molecular Weight | 412.7 g/mol |
| Synonyms | 4-[5-[bis(2-chloroethyl)amino]-1-methylbenzimidazol-2-yl]butanoic acid;hydrate;hydrochloride |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Bendamustine hydrochloride monohydrate, a type of chemotherapy drug, is an alkylating agent used to treat certain types of cancer, particularly chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL).
The listed CAS number is 1374784-02-7.
The listed molecular formula is C16H24Cl3N3O3.
The listed molecular weight is 412.7 g/mol.
4-[5-[bis(2-chloroethyl)amino]-1-methylbenzimidazol-2-yl]butanoic acid;hydrate;hydrochloride.
The source lists Treakisym (TN), 1H-Benzimidazole-2-butanoic acid, 5-(bis(2-chloroethyl)amino)-1-methyl-, hydrochloride and hydrate.